All In Biotech

Drug Trial Radar · NCT01846273

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Last checked: Nov 20, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

321

Actual

Start

Aug 7, 2013

Primary completion

Mar 11, 2016

Study completion Mar 2, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (PCV). The results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with PCV.

Conditions

  • Age-related Macular Degeneration
  • Polypoidal Choroidal Vasculopathy

Interventions

  • RanibizumabDrug

    Intravitreal injection of 0.5 mg ranibizumab

  • Verteporfin PDTDrug

    Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)

  • Sham PDTDrug

    Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study EyeTime frame: Baseline, Month 12
  2. Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study EyeTime frame: Baseline, Month 12

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Chiba, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, Japan

  • Novartis Investigative Site

    Fukushima, Fukushima, Japan

  • Novartis Investigative Site

    Maebashi, Gunma, Japan

  • Novartis Investigative Site

    Amagasaki, Hyōgo, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, Japan

  • Novartis Investigative Site

    Inashiki-gun, Ibaraki, Japan

  • Novartis Investigative Site

    Kita-gun, Kagawa-ken, Japan

  • Novartis Investigative Site

    Sakyo-ku, Kyoto, Japan

  • Novartis Investigative Site

    Tsu, Mie-ken, Japan

  • Novartis Investigative Site

    Okayama, Okayama-ken, Japan

  • Novartis Investigative Site

    Hirakata, Osaka, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Ohtsu-city, Shiga, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, Japan

  • Novartis Investigative Site

    Mitaka, Tokyo, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site

    Batu Caves, Selangor, Malaysia

  • Novartis Investigative Site

    Petaling Jaya, Selangor, Malaysia

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seongnam-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Seoul, Seocho-gu, South Korea

  • Novartis Investigative Site

    Changhua, Taiwan

  • Novartis Investigative Site

    Kaohsiung City, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Taoyuan, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan, ROC, Taiwan

  • Novartis Investigative Site

    Bangkok, Thailand

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.